These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34437954)

  • 1. Perspectives on the elimination of animal assays in the assessment of carcinogenicity.
    Nishikawa A
    Regul Toxicol Pharmacol; 2021 Nov; 126():105031. PubMed ID: 34437954
    [No Abstract]   [Full Text] [Related]  

  • 2. Alternatives to the carcinogenicity bioassay: in silico methods, and the in vitro and in vivo mutagenicity assays.
    Benigni R; Bossa C; Tcheremenskaia O; Giuliani A
    Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):809-19. PubMed ID: 20438313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medium-term bioassays in rats for rapid detection of the carcinogenic potential of chemicals.
    Shirai T; Hirose M; Ito N
    IARC Sci Publ; 1999; (146):251-72. PubMed ID: 10353390
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro carcinogenicity testing: present and future perspectives in pharmaceutical development.
    Kowalski LA
    Curr Opin Drug Discov Devel; 2001 Jan; 4(1):29-35. PubMed ID: 11727320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of alternative methods of carcinogenicity testing and evaluation of human pharmaceuticals.
    Van Deun K; Van Cauteren H; Vandenberghe J; Canning M; Vanparys P; Coussement W
    Adverse Drug React Toxicol Rev; 1997 Nov; 16(4):215-33. PubMed ID: 9608857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of mammalian cell mutation assays in mutagenicity and carcinogenicity testing.
    Arlett CF; Cole J
    Mutagenesis; 1988 Nov; 3(6):455-8. PubMed ID: 3070282
    [No Abstract]   [Full Text] [Related]  

  • 7. Opportunities for an alternative integrating testing strategy for carcinogen hazard assessment?
    Doktorova TY; Pauwels M; Vinken M; Vanhaecke T; Rogiers V
    Crit Rev Toxicol; 2012 Feb; 42(2):91-106. PubMed ID: 22141324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotoxicity and carcinogenicity studies of antihistamines.
    Brambilla G; Mattioli F; Robbiano L; Martelli A
    Arch Toxicol; 2011 Oct; 85(10):1173-87. PubMed ID: 21327970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic assays for mutations and cancer: current status and future perspectives.
    Vijg J; van Steeg H
    Mutat Res; 1998 May; 400(1-2):337-54. PubMed ID: 9685694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotoxicity and carcinogenicity testing of pharmaceuticals: correlations between induction of DNA lesions and carcinogenic activity.
    Brambilla G; Mattioli F; Robbiano L; Martelli A
    Mutat Res; 2010; 705(1):20-39. PubMed ID: 20206292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: analysis of pharmaceutical experience with decades of rat carcinogenicity testing. Introduction to article by Sistare et al.
    Morton D; Alden CL
    Toxicol Pathol; 2011 Jun; 39(4):715. PubMed ID: 21666102
    [No Abstract]   [Full Text] [Related]  

  • 12. International regulatory needs for development of an IATA for non-genotoxic carcinogenic chemical substances.
    Jacobs MN; Colacci A; Louekari K; Luijten M; Hakkert BC; Paparella M; Vasseur P
    ALTEX; 2016; 33(4):359-392. PubMed ID: 27120445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International prevalidation study on cell transformation assay. Preface.
    Corvi R; Vanparys P
    Mutat Res; 2012 Apr; 744(1):1-2. PubMed ID: 22387843
    [No Abstract]   [Full Text] [Related]  

  • 14. Design and evaluation of rodent carcinogenicity studies (bioassay).
    Usui T
    J Toxicol Sci; 1995 Sep; 20(4):457-8. PubMed ID: 8531240
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of 17 methods of predicting the carcinogenicity of 30 chemicals.
    Ashby J
    Environ Health Perspect; 1997 May; 105(5):466-7. PubMed ID: 9222126
    [No Abstract]   [Full Text] [Related]  

  • 16. Carcinogenicity and mutagenicity testing, then and now.
    Weisburger JH
    Mutat Res; 1999 Sep; 437(2):105-12. PubMed ID: 10556615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long- and medium-term carcinogenicity studies in animals and short-term genotoxicity tests.
    Feron VJ; Schwarz M; Hemminki K; Krewski D
    IARC Sci Publ; 1999; (131):103-29. PubMed ID: 10505295
    [No Abstract]   [Full Text] [Related]  

  • 18. An assessment of the utility of the yeast GreenScreen assay in pharmaceutical screening.
    Van Gompel J; Woestenborghs F; Beerens D; Mackie C; Cahill PA; Knight AW; Billinton N; Tweats DJ; Walmsley RM
    Mutagenesis; 2005 Nov; 20(6):449-54. PubMed ID: 16291732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro mammalian cell genotoxicity assays: their use and interpretation.
    McGregor D
    Prog Clin Biol Res; 1990; 340B():159-69. PubMed ID: 2203003
    [No Abstract]   [Full Text] [Related]  

  • 20. Prolactin-induced mammary tumorigenesis is not a rodent-specific response.
    Harvey PW
    Toxicol Pathol; 2011 Oct; 39(6):1020-2. PubMed ID: 21971937
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.